# Immunovant, Inc.: financial statements, quarterly

IMVT · Nasdaq · CIK 1764013 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/imvt.md) · [Financials](/companies/imvt/financials.md) · [Filings](/companies/imvt/filings.md) · [Insiders](/companies/imvt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/imvt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.5](/filings/0001764013-24-000184.md) | [(0.1)](/filings/0001764013-25-000026.md) | [0.2 d](/filings/0001764013-26-000064.md) | [0.1](/filings/0001764013-25-000129.md) | [0.1](/filings/0001764013-25-000149.md) | [0.2](/filings/0001764013-26-000011.md) | [0.6 d](/filings/0001764013-26-000064.md) | [0.9](/filings/0001764013-26-000101.md) | [0.6](/filings/0001764013-25-000149.md) | [1.6](/filings/0001764013-26-000011.md) | [(2.8) d](/filings/0001764013-26-000064.md) | [0.0](/filings/0001764013-26-000101.md) |
| Net income | $m | [(58.7)](/filings/0001764013-25-000026.md) | [(51.4)](/filings/0001764013-25-000026.md) | [(75.3) d](/filings/0001764013-26-000064.md) | [(87.2)](/filings/0001764013-26-000011.md) | [(109)](/filings/0001764013-26-000011.md) | [(111)](/filings/0001764013-26-000011.md) | [(106) d](/filings/0001764013-26-000064.md) | [(121)](/filings/0001764013-26-000101.md) | [(127)](/filings/0001764013-26-000011.md) | [(111)](/filings/0001764013-26-000011.md) | [(148) d](/filings/0001764013-26-000064.md) | [(153)](/filings/0001764013-26-000101.md) |
| Diluted EPS | $ per share | [(0.45)](/filings/0001764013-24-000184.md) | [(0.36)](/filings/0001764013-25-000026.md) | not reported | [(0.60)](/filings/0001764013-25-000129.md) | [(0.74)](/filings/0001764013-25-000149.md) | [(0.76)](/filings/0001764013-26-000011.md) | not reported | [(0.71)](/filings/0001764013-26-000101.md) | [(0.73)](/filings/0001764013-25-000149.md) | [(0.61)](/filings/0001764013-26-000011.md) | not reported | [(0.75)](/filings/0001764013-26-000101.md) |
| Basic EPS | $ per share | [(0.45)](/filings/0001764013-24-000184.md) | [(0.36)](/filings/0001764013-25-000026.md) | not reported | [(0.60)](/filings/0001764013-25-000129.md) | [(0.74)](/filings/0001764013-25-000149.md) | [(0.76)](/filings/0001764013-26-000011.md) | not reported | [(0.71)](/filings/0001764013-26-000101.md) | [(0.73)](/filings/0001764013-25-000149.md) | [(0.61)](/filings/0001764013-26-000011.md) | not reported | [(0.75)](/filings/0001764013-26-000101.md) |

- Research and development: not reported
- Operating income: not reported
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [270](/filings/0001764013-23-000133.md) | [691](/filings/0001764013-24-000026.md) | [635](/filings/0001764013-25-000092.md) | [560](/filings/0001764013-24-000148.md) | [473](/filings/0001764013-24-000184.md) | [375](/filings/0001764013-25-000026.md) | [714](/filings/0001764013-26-000064.md) | [599](/filings/0001764013-25-000129.md) | [522](/filings/0001764013-25-000149.md) | [995](/filings/0001764013-26-000011.md) | [902](/filings/0001764013-26-000101.md) | [798](/filings/0001764013-26-000101.md) |
| Current assets | $m | [291](/filings/0001764013-23-000133.md) | [711](/filings/0001764013-24-000026.md) | [666](/filings/0001764013-25-000092.md) | [589](/filings/0001764013-24-000148.md) | [507](/filings/0001764013-24-000184.md) | [413](/filings/0001764013-25-000026.md) | [768](/filings/0001764013-26-000064.md) | [652](/filings/0001764013-25-000129.md) | [574](/filings/0001764013-25-000149.md) | [1,043](/filings/0001764013-26-000011.md) | [949](/filings/0001764013-26-000101.md) | [851](/filings/0001764013-26-000101.md) |
| Total assets | $m | [292](/filings/0001764013-23-000133.md) | [711](/filings/0001764013-24-000026.md) | [666](/filings/0001764013-25-000092.md) | [590](/filings/0001764013-24-000148.md) | [516](/filings/0001764013-24-000184.md) | [421](/filings/0001764013-25-000026.md) | [776](/filings/0001764013-26-000064.md) | [661](/filings/0001764013-25-000129.md) | [583](/filings/0001764013-25-000149.md) | [1,052](/filings/0001764013-26-000011.md) | [957](/filings/0001764013-26-000101.md) | [852](/filings/0001764013-26-000101.md) |
| Current liabilities | $m | [40.3](/filings/0001764013-23-000133.md) | [32.1](/filings/0001764013-24-000026.md) | [48.6](/filings/0001764013-25-000092.md) | [45.0](/filings/0001764013-24-000148.md) | [66.7](/filings/0001764013-24-000184.md) | [68.3](/filings/0001764013-25-000026.md) | [68.8](/filings/0001764013-26-000064.md) | [52.9](/filings/0001764013-25-000129.md) | [63.3](/filings/0001764013-25-000149.md) | [66.3](/filings/0001764013-26-000011.md) | [104](/filings/0001764013-26-000101.md) | [117](/filings/0001764013-26-000101.md) |
| Total liabilities | $m | [40.3](/filings/0001764013-23-000133.md) | [32.1](/filings/0001764013-24-000026.md) | [48.6](/filings/0001764013-25-000092.md) | [45.0](/filings/0001764013-24-000148.md) | [66.7](/filings/0001764013-24-000184.md) | [68.3](/filings/0001764013-25-000026.md) | [68.8](/filings/0001764013-26-000064.md) | [52.9](/filings/0001764013-25-000129.md) | [63.3](/filings/0001764013-25-000149.md) | [66.3](/filings/0001764013-26-000011.md) | [104](/filings/0001764013-26-000101.md) | [117](/filings/0001764013-26-000101.md) |
| Shareholders' equity | $m | [252](/filings/0001764013-25-000026.md) | [679](/filings/0001764013-25-000026.md) | [618](/filings/0001764013-26-000064.md) | [545](/filings/0001764013-26-000011.md) | [449](/filings/0001764013-26-000011.md) | [353](/filings/0001764013-26-000011.md) | [707](/filings/0001764013-26-000101.md) | [609](/filings/0001764013-26-000101.md) | [520](/filings/0001764013-26-000011.md) | [986](/filings/0001764013-26-000011.md) | [853](/filings/0001764013-26-000101.md) | [735](/filings/0001764013-26-000101.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(60.1) d](/filings/0001764013-24-000184.md) | [(47.1) d](/filings/0001764013-25-000026.md) | [(59.7) d](/filings/0001764013-26-000064.md) | [(76.2)](/filings/0001764013-25-000129.md) | [(88.6) d](/filings/0001764013-25-000149.md) | [(100) d](/filings/0001764013-26-000011.md) | [(111) d](/filings/0001764013-26-000064.md) | [(117)](/filings/0001764013-26-000101.md) | [(103) d](/filings/0001764013-25-000149.md) | [(92.3) d](/filings/0001764013-26-000011.md) | [(95.1) d](/filings/0001764013-26-000064.md) | [(124)](/filings/0001764013-26-000101.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001764013-24-000184.md) | [0.1 d](/filings/0001764013-25-000026.md) | [0.2 d](/filings/0001764013-26-000064.md) | [0.2](/filings/0001764013-25-000129.md) | [0.2 d](/filings/0001764013-25-000149.md) | [0.2 d](/filings/0001764013-26-000011.md) | [0.2 d](/filings/0001764013-26-000064.md) | [0.0](/filings/0001764013-25-000129.md) | [0.0 d](/filings/0001764013-25-000149.md) | [0.0 d](/filings/0001764013-26-000011.md) | [0.0 d](/filings/0001764013-26-000064.md) | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [117](/filings/0001764013-23-000133.md) | [129](/filings/0001764013-24-000026.md) | [131](/filings/0001764013-24-000148.md) | [131](/filings/0001764013-24-000184.md) | [145](/filings/0001764013-25-000026.md) | [146](/filings/0001764013-25-000129.md) | [146](/filings/0001764013-25-000149.md) | [147](/filings/0001764013-26-000011.md) | [171](/filings/0001764013-26-000101.md) | [174](/filings/0001764013-25-000149.md) | [182](/filings/0001764013-26-000011.md) | [206](/filings/0001764013-26-000101.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 206,552,682 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001764013-26-000101.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.